Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases.

Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy.

Five year results of selective patellar resurfacing in cruciate sparing total knee replacements.

We performed a prospective study on 129 knees with a selective approach to patellar resurfacing. One hundred and five knees were followed up at an average of 57 months. Of these, 48 knees met the eligibility criteria, thus leaving 57 knees with unresurfaced patellas.